JP2022512874A5 - - Google Patents
Info
- Publication number
- JP2022512874A5 JP2022512874A5 JP2021523668A JP2021523668A JP2022512874A5 JP 2022512874 A5 JP2022512874 A5 JP 2022512874A5 JP 2021523668 A JP2021523668 A JP 2021523668A JP 2021523668 A JP2021523668 A JP 2021523668A JP 2022512874 A5 JP2022512874 A5 JP 2022512874A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- formula
- composition according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306499.7 | 2018-11-15 | ||
| EP18306499 | 2018-11-15 | ||
| PCT/EP2019/081516 WO2020099650A1 (en) | 2018-11-15 | 2019-11-15 | Madrasin-derivative compounds, composition and uses thereof for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512874A JP2022512874A (ja) | 2022-02-07 |
| JP2022512874A5 true JP2022512874A5 (https=) | 2022-11-24 |
| JP7636322B2 JP7636322B2 (ja) | 2025-02-26 |
Family
ID=64564768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523668A Active JP7636322B2 (ja) | 2018-11-15 | 2019-11-15 | 癌を処置するためのマドラシン誘導体化合物、組成物およびこれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12213978B2 (https=) |
| EP (1) | EP3880205B1 (https=) |
| JP (1) | JP7636322B2 (https=) |
| KR (1) | KR20210124187A (https=) |
| CN (1) | CN113226323B (https=) |
| AU (1) | AU2019379310B2 (https=) |
| CA (1) | CA3118222A1 (https=) |
| IL (1) | IL282692B2 (https=) |
| WO (1) | WO2020099650A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020243519A1 (en) * | 2019-05-29 | 2020-12-03 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2021231908A2 (en) * | 2020-05-15 | 2021-11-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhancing cancer immunotherapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012007872A (es) * | 2010-01-06 | 2012-10-03 | Joseph P Errico | Metodos y composiciones de desarrollo de farmacos dirigidos. |
| CA3017641C (en) * | 2016-03-25 | 2023-12-12 | Charles J. Bieberich | Pim kinase inhibitors in combination with rna splicing modulators/inhibitors for treatment of cancers |
-
2019
- 2019-11-15 JP JP2021523668A patent/JP7636322B2/ja active Active
- 2019-11-15 EP EP19801384.9A patent/EP3880205B1/en active Active
- 2019-11-15 IL IL282692A patent/IL282692B2/en unknown
- 2019-11-15 KR KR1020217018289A patent/KR20210124187A/ko not_active Ceased
- 2019-11-15 CA CA3118222A patent/CA3118222A1/en active Pending
- 2019-11-15 CN CN201980074485.XA patent/CN113226323B/zh active Active
- 2019-11-15 US US17/293,506 patent/US12213978B2/en active Active
- 2019-11-15 AU AU2019379310A patent/AU2019379310B2/en active Active
- 2019-11-15 WO PCT/EP2019/081516 patent/WO2020099650A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102800132B1 (ko) | Sting 작동 화합물 | |
| ES2527176T3 (es) | Compuestos y composiciones como inhibidores de proteína quinasa | |
| JP2023520333A5 (https=) | ||
| JP5886411B2 (ja) | 新規のピリミジン誘導体 | |
| CN113316574A (zh) | Shp2抑制剂及其应用 | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| RU2006122853A (ru) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы | |
| JP2014503567A5 (https=) | ||
| JP2019535746A5 (https=) | ||
| JP2018505880A5 (https=) | ||
| JP2018507197A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| JP2006501201A5 (https=) | ||
| JP2014518544A5 (https=) | ||
| JP2013528174A5 (https=) | ||
| CN111818925A (zh) | Cdk4/6抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途 | |
| JP2022512874A5 (https=) | ||
| JP2024125139A5 (https=) | ||
| CN114728994A (zh) | 芳基磷氧类化合物及其用途 | |
| CN101484443A (zh) | 放射线治疗增强剂 | |
| EP2897952A1 (en) | 4-(indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer | |
| CA2602199A1 (en) | Heteroaryl urea derivatives useful for inhibiting chk1 | |
| CA3119036A1 (en) | Anti-cancer activity of adamantane derivatives | |
| JP2016502540A5 (https=) |